Clinical trial
An Extension Study to Evaluate Avastin in Patients Treated in a Previous…
NCT00109057 · Genentech, Inc., Industry · Completed
Key facts
| NCT number | NCT00109057 |
|---|---|
| Title | An Extension Study to Evaluate Avastin in Patients Treated in a Previous Genentech-Sponsored Cancer Study |
| Official title | An Open-Label, Multicenter Extension Study of Recombinant Humanized Monoclonal Anti-VEGF Antibody (rhuMAb VEGF, Bevacizumab) in Subjects Treated With rhuMAb VEGF in a Previous Genentech-Sponsored Phase I or Phase II Cancer Study |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cancer |
| Intervention type | Drug |
| Interventions | Avastin (bevacizumab) |
| Enrollment | 56 |
| Start date | Feb 1, 1998 |
| Completion | Feb 1, 2004 |
| First posted | Apr 25, 2005 |
| Last update posted | Jun 21, 2013 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: